These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 23838916)

  • 21. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
    Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis].
    Langer R; Specht K; Becker K; Ewald P; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
    Verh Dtsch Ges Pathol; 2004; 88():207-13. PubMed ID: 16892554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling.
    Shen LY; Wang H; Dong B; Yan WP; Lin Y; Shi Q; Chen KN
    Oncotarget; 2016 Jan; 7(4):4531-41. PubMed ID: 26673820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2α expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Eralp Y; Keskin S; Akışık E; Akışık E; İğci A; Müslümanoğlu M; Yılmaz S; Tunacı M; Çamlıca H; Tuzlalı S; Saip P; Dalay N; Özmen V; Topuz E
    Am J Clin Oncol; 2013 Jun; 36(3):215-23. PubMed ID: 22441341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiRNAs and their association with locoregional staging and survival following surgery for esophageal carcinoma.
    Hummel R; Hussey DJ; Michael MZ; Haier J; Bruewer M; Senninger N; Watson DI
    Ann Surg Oncol; 2011 Jan; 18(1):253-60. PubMed ID: 20628822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.
    Yamasaki M; Miyata H; Fujiwara Y; Takiguchi S; Nakajima K; Nishida T; Yasuda T; Matsuyama J; Mori M; Doki Y
    Ann Surg Oncol; 2010 Feb; 17(2):634-42. PubMed ID: 19941080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
    Sujendran V; Wheeler J; Baron R; Warren BF; Maynard N
    Br J Surg; 2008 Feb; 95(2):191-4. PubMed ID: 17948302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
    Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
    Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer.
    Winther M; Alsner J; Tramm T; Baeksgaard L; Holtved E; Nordsmark M
    Acta Oncol; 2015; 54(9):1582-91. PubMed ID: 26481465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Joshi MB; Shirota Y; Danenberg KD; Conlon DH; Salonga DS; Herndon JE; Danenberg PV; Harpole DH
    Clin Cancer Res; 2005 Mar; 11(6):2215-21. PubMed ID: 15788669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multimodal approach for cervical esophageal carcinoma: role of neoadjuvant chemotherapy.
    Suzuki G; Yamazaki H; Ogo E; Abe T; Eto H; Muraki K; Hattori C; Umeno H; Nakashima T; Tanaka T; Nakamura S; Yoshida K
    Anticancer Res; 2014 Apr; 34(4):1989-92. PubMed ID: 24692736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
    Mariette C; Taillier G; Van Seuningen I; Triboulet JP
    Ann Thorac Surg; 2004 Oct; 78(4):1177-83. PubMed ID: 15464466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma.
    Hong L; Han Y; Zhang H; Li M; Gong T; Sun L; Wu K; Zhao Q; Fan D
    Ann Surg; 2010 Jun; 251(6):1056-63. PubMed ID: 20485139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
    Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overregulation of microRNA-212 in the poor prognosis of esophageal cancer patients.
    Qi B; Liu SG; Qin XG; Yao WJ; Lu JG; Guo L; Wang TY; Li HC; Zhao BS
    Genet Mol Res; 2014 Sep; 13(3):7800-7. PubMed ID: 25299094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
    Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
    Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus.
    Kajiwara T; Nishina T; Hyodo I; Moriwaki T; Endo S; Nasu J; Hori S; Matsuura B; Hiasa Y; Onji M
    Oncology; 2009; 76(5):342-9. PubMed ID: 19307741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
    Miyoshi N; Yano M; Takachi K; Kishi K; Noura S; Eguchi H; Yamada T; Miyashiro I; Ohue M; Ohigashi H; Sasaki Y; Ishikawa O; Doki Y; Imaoka S
    J Surg Oncol; 2009 Apr; 99(5):302-6. PubMed ID: 19170110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.
    Sakai M; Kato H; Sano A; Tanaka N; Inose T; Kimura H; Sohda M; Nakajima M; Kuwano H
    Ann Surg Oncol; 2009 Sep; 16(9):2494-501. PubMed ID: 19526206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.